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Varicose veins occur commonly in the general population but, MTHFR is an enzyme that is important in homocysteinemetabolism.
despite much research, the etiology of venous disease is still poorly
understood. The pathogenesis of the vein dilatation remains obscure
in spite of the evidence of a primary defect in the vein wall. A number
of epidemiological studies have shown that, in addition to environmen-
tal factors, genetic mechanisms may play a role in determining suscep-
tibility to vascular disease. In particular, abnormalities in the enzymes
that control homocysteine metabolism have been shown to cause vas-
cular disease (Sverdlova et al., 1998; Kim et al., 2007).
Wilmanns et al. (2015) present here a fundamental insight into the
nature of primary varicose vein disease. They attempt to determine if
the methylenetetrahydrofolate reductase polymorphisms (MTHFR
C677T and A1298C) are implied in themorphology and types of compli-
cated disease in patients with primary varicose veins. The C677T
polymorphism is located in the catalytic domain of the protein, the
binding site for the MTHFR co-factor Flavin adenine dinucleotide. This
polymorphism is associated with an enhancement of the thermolability
of the enzyme, a reduction of the activity, an increase of plasma homo-
cysteine concentrations, and a decreased in plasma folate (Frosst
et al., 1995). The second MTHFR polymorphism A1298C lies in the
C-terminal end of the enzyme, the S-adenosylmethionine regulatory
domain, andmay result in a decrease of 40% in enzyme activity of the
variant genotype (Weisberg et al., 2002). Both polymorphisms have
been found to be implicated in colon cancer risk and the response to
5-FU chemotherapy, sinceMTHFR is implicated in the FUmetabolism
(Fernández-Peralta et al., 2010; Delgado-Plasencia et al., 2013). Also,
these polymorphisms have been previously implicated in thrombotic
disease (Milio et al., 2008; Wilmanns et al., 2011). Authors argued
that different genetic origins may be the cause for the morphological
types, trunk and perforator, of complicated and uncomplicated disease.
In the study, the authors provide a hypothesis for the impact of MTHFR
polymorphisms C677T and A1298C as hereditary components of
primary varicose vein disease. They establish an interesting association:
the axial trunk typemorphologywas almost exclusively associatedwith
homozygosity (TT) or heterozygosity in C677T, while the perforator
type morphology with homozygosity (CC) or heterozygosity in A1298C.
Additionally, double heterozygosity CT (C677T) and AC (A1298C) are
associated with the combined trunk and perforator phenotype. On the
other hand, there is an increased risk of CEAP C3-6 complication from
AA to CC genotype at the A1298C polymorphism.DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.01.006.
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phic variants) could lead to elevated levels of homocysteine, free radical
formation, and endothelial damage. This could potentially lead to oxida-
tive stress and dysfunctional endothelium. Although this paper suggests
that theremay be a link betweenMTHFR in the pathogenesis of varicose
vein disease and its thrombotic complications, further studies should be
conducted to conﬁrm these associations in other series, in order to clar-
ify how MTHFR inﬂuences the pathogenesis of varicose veins and the
risk increase for developing the disease.
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